Roche secures EC approval for Columvi to treat R/R DCLBCL in adults
Columvi is a T-cell-engaging bispecific antibody engineered to have one region that binds to CD3, a protein on…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Jul 23
Columvi is a T-cell-engaging bispecific antibody engineered to have one region that binds to CD3, a protein on…
12 Jul 23
The decision was made by the firm after consultation with the data monitoring committee regarding results data from…
12 Jul 23
The financing will support the progression of Septerna’s lead programme, which targets the parathyroid hormone 1 receptor (PTH1R),…
11 Jul 23
Janssen will obtain an exclusive license to develop and commercialise the NBTXR3 worldwide, in exchange for up to…
11 Jul 23
PRX005 is an anti-tau antibody that specifically targets a region in the microtubule binding region of tau to…
11 Jul 23
Under the agreement, BeiGene will buy an exclusive option for a global clinical and commercial license to DualityBio’s…
11 Jul 23
The objective of the partnership between Evotec and Bristol Myers Squibb is to identify disease-modifying treatments for diverse…
11 Jul 23
Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of…
11 Jul 23
Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 mL prefilled syringes
10 Jul 23
ZyVersa’s Cholesterol Efflux Mediator VAR 200 is currently in Phase 2a development to reduce renal cholesterol and lipid…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates